SODIUM THIOSALICYLATE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C7H5O2S.Na
Molecular Weight	176.168
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Na+].[O-]C(=O)C1=C(S)C=CC=C1

InChI

InChIKey=HBAIZOJDXAXWHS-UHFFFAOYSA-M

InChI=1S/C7H6O2S.Na/c8-7(9)5-3-1-2-4-6(5)10;/h1-4,10H,(H,8,9);/q;+1/p-1

HIDE SMILES / InChI

Description
Sources: ISBN: 978-0-7637-6547-7, 'Nurse's Drug 2009' (2009), p. 949, Retrieved from https://books.google.com/books?id=pobp8JRNW1MC&pg | https://www.ncbi.nlm.nih.gov/pubmed/13563950

Thiosalicylic acid is an analgesic and anti-inflammatory agent. It is used (in form of sodium salt) to relieve symptoms of acute gout, painful musculoskeletal conditions, osteoarthritis and rheumatic fever. The drug exerts its action by inhibiting prostaglandin synthesis. Thiosalicylic acid usage is associated with the risk of contact dermatitis.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
prostaglandin biosynthetic process 23 Target ID: GO:0001516 Sources: ISBN: 978-0-7637-6547-7, 'Nurse's Drug 2009' (2009), p. 949, Retrieved from https://books.google.com/books?id=pobp8JRNW1MC&pg	Inhibitor 8297

Conditions

Condition	Modality	Highest Phase	Product
Acute gout 3 Sources: (2009) 'Nurse's Drug 2009', p. 949, retrieved from: https://books.google.com/books?id=pobp8JRNW1MC&pg	Palliative	Not Provided 504	REXOLATE Approved Use To relieve symptoms of acute gout, to relieve pain from musculoskeletal conditions, to relieve symptoms of osteoarthritis, to treat rheumatic fever.
Musculoskeletal conditions 6 Sources: (2009) 'Nurse's Drug 2009', p. 949, retrieved from: https://books.google.com/books?id=pobp8JRNW1MC&pg	Palliative	Not Provided 504	REXOLATE Approved Use To relieve symptoms of acute gout, to relieve pain from musculoskeletal conditions, to relieve symptoms of osteoarthritis, to treat rheumatic fever.
Osteoarthritis 157 Sources: (2009) 'Nurse's Drug 2009', p. 949, retrieved from: https://books.google.com/books?id=pobp8JRNW1MC&pg	Palliative	Not Provided 504	REXOLATE Approved Use To relieve symptoms of acute gout, to relieve pain from musculoskeletal conditions, to relieve symptoms of osteoarthritis, to treat rheumatic fever.
Rheumatic fever 6 Sources: (2009) 'Nurse's Drug 2009', p. 949, retrieved from: https://books.google.com/books?id=pobp8JRNW1MC&pg	Primary	Not Provided 504	REXOLATE Approved Use To relieve symptoms of acute gout, to relieve pain from musculoskeletal conditions, to relieve symptoms of osteoarthritis, to treat rheumatic fever.

PubMed

Title	Date	PubMed
Using model complexes to augment and advance metalloproteinase inhibitor design.	2004 May 17	15132609
Chelating sorbents based on silica gel and their application in atomic spectrometry.	2005 Mar	15703917
Determination of mercury complexation in coastal and estuarine waters using competitive ligand exchange method.	2005 Sep 1	16190218
In vitro-refolding of a single-chain Fv fragment in the presence of heteroaromatic thiols.	2008 Apr 30	18321603
Natural products as an inspiration in the diversity-oriented synthesis of bioactive compound libraries.	2008 Aug	18663392
[1,2-Bis(diphenyl-phosphino)ethane-κP,P'](2-carboxyl-atothio-phenolato-κO,S)nickel(II) methanol solvate.	2009 Jan 8	21581768
The Ras inhibitor farnesylthiosalicyclic acid (FTS) prevents nodule formation and development of preneoplastic foci of altered hepatocytes in rats.	2009 Jul	19427195
Expression of metallothionein mRNAs on mouse cerebellum microglia cells by thimerosal and its metabolites.	2009 Jun 30	19386279
Mercury exposure, nutritional deficiencies and metabolic disruptions may affect learning in children.	2009 Oct 27	19860886
2-[(2-Carboxy-phen-yl)sulfan-yl]acetic acid.	2009 Sep 5	21577786
Poly[(dimethyl-formamide)(μ(4)-2,2'-sulfanediyldibenzoato)nickel(II)].	2010 Mar 6	21580481
2-[(2-Carboxy-phen-yl)disulfan-yl]benzoic acid-4,4'-bipyridyl N,N'-dioxide (1/2).	2010 May 26	21579515
14-(1,3-Benzodioxol-5-yl)-7,14-dihydro-dibenzo[a,j]acridine.	2010 Nov 6	21589382

Patents

Sample Use Guides

In Vivo Use Guide

Acute gout: initial dose is 100 mg every 3 to 4 hours for 2 days, then 100 mg daily. Painful musculoskeletal conditions: 50 to 100 mg daily or every other day. Osteoarthritis: 10 mg 3 times/week for several weeks then once a week, usually up to a total dosage of 2.5 g. Rheumatic fever: initial dose is 100 to 150 mg every 4 to 8 hours for 3 days, then 100 mg two times daily.

Route of Administration: Other

In Vitro Use Guide

Human platelets were incubated with thiosalicylic acid at 0.5 mM for 3 min in the presence of 1,2 and 1,3-glyceryl dinitrate. A concentration-dependent inhibition of platelet aggregation was observed.

Name

Type

Language

SODIUM THIOSALICYLATE

Systematic Name

English

SODIUM 2-SULFANYLBENZOATE

Systematic Name

English

SODIUM THIOSALICYLATE [MART.]

Common Name

English

Sodium thiosalicylate [WHO-DD]

Common Name

English

SODIUM THIOSALICYLATE [VANDF]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C257